Drug treatment for facioscapulohumeral muscular dystrophy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Facioscapulohumeral muscular dystrophy is a progressive muscle disease which has no agreed treatment. Early suggestions that corticosteroids might be helpful were not supported by a subsequent open label study. The beta 2 adrenergic agonist albuterol, also known as salbutamol, is known to have anabolic effects which might be beneficial for facioscapulohumeral muscular dystrophy. Creatine has been used as a muscle performance enhancer by athletes and it might be helpful in muscular dystrophies including facioscapulohumeral muscular dystrophy. OBJECTIVES: The objective of the review was to determine whether there is any drug treatment which alters the progression of facioscapulohumeral muscular dystrophy. SEARCH STRATEGY: We searched the Cochrane Neuromuscular Disease Group specialised register (searched August 2003), MEDLINE (January 1966 to August 2003) and EMBASE (January 1980 to August 2003) for any references to facioscapulohumeral muscular dystrophy. Abstracts from the major neurological meetings and trial bibliographies were also searched for further references to trials. Experts were contacted for information regarding unpublished trials or trials in progress. SELECTION CRITERIA: We included all randomised or quasi-randomised trials of any drug treatment for facioscapulohumeral muscular dystrophy, in adults with a recognised diagnosis of facioscapulohumeral muscular dystrophy. Trials had to include an assessment of muscle strength at one year. DATA COLLECTION AND ANALYSIS: All identified trials were independently assessed by both reviewers to ensure that they fulfilled the selection criteria and were then rated for their quality. Trial data were extracted and entered by one reviewer and checked by the other. If appropriate data existed a weighted treatment effect was to be calculated across trials using the Cochrane statistical package, Review Manager. The results were to have been expressed as relative risks and 95% confidence intervals and risk differences and 95% confidence intervals for dichotomous outcomes, and weighted mean differences and 95% confidence intervals for continuous outcomes. MAIN RESULTS: Two published high quality randomised controlled trials fulfilled the selection criteria. One compared creatine supplementation with placebo and the other compared high and low-dose albuterol with placebo. A further unpublished randomised controlled trial of albuterol in facioscapulohumeral muscular dystrophy was identified. The creatine trial showed a non-significant difference in favour of creatine. The albuterol trial showed no significant difference in muscle strength at one year but some secondary measures such as lean body mass and handgrip strength did improve. REVIEWERS' CONCLUSIONS: There is no evidence from randomised controlled trials to support any drug treatment for facioscapulohumeral muscular dystrophy but only two randomised controlled trials have been published.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation
Harris, R. C., Söderlund, K., & Hultman, E. (1992) · Clinical Science · doi:10.1042/cs0830367 · Cited by 1,168 · cited 2×
“Indeed healthy adults taking creatine supplements have shown improved muscle force (GreenhaH 1993; Kamber 1999; Maganaris 1998; Tarnopolsky 2000) and increased lean body mass (most of which is muscle) (Harris 1992; Hultman 1996; Mihic 2000).”
BackgroundGreenhaff, P. L., Casey, A., Short, A. H., Harris, R., Soderlund, K., & Hultman, E. (1993) · Clinical Science · doi:10.1042/cs0840565 · Cited by 460
Parise, G., Mihic, S., MacLennan, D., Yarasheski, K. E., & Tarnopolsky, M. A. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.91.3.1041 · Cited by 236 · cited 2×
“Creatine plays an important role in muscle energy metabolism (Wallimann 1992) and may play a role in the regulation of protein metabolism (Parise 2001).”
BackgroundMIHIC, S., MacDONALD, J. R., McKENZIE, S., & TARNOPOLSKY, M. A. (2000) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200002000-00007 · Cited by 201
Tarnopolsky, M. A., & MacLennan, D. P. (2000) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.10.4.452 · Cited by 113
MAGANARIS, C. N., & MAUGHAN, R. J. (1998) · Acta Physiologica Scandinavica · doi:10.1046/j.1365-201x.1998.00395.x · Cited by 98 · cited 2×
“[MEDLINE: 2160] Maganaris 1998 Maganaris CN, Maughan RJ. Creatine supplementation enhances maximum voluntary isometric force and endurance capacity in resistance trained men.”
Background
Cited by
Facioscapulohumeral muscular dystrophy
Tawil, R., & Van Der Maarel, S. M. (2006) · Muscle & Nerve · doi:10.1002/mus.20522 · Cited by 441
Self-citationCreatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169
Pandya, S., King, W. M., & Tawil, R. (2008) · Physical Therapy · doi:10.2522/ptj.20070104 · Cited by 76
Self-citationCreatine for treating muscle disorders
Kley, R. A., Vorgerd, M., & Tarnopolsky, M. A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub2 · Cited by 45
Creatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub3 · Cited by 38
Metadata
- Authors
- Rose, M. R., & Tawil, R.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2004-04-19
- Volume
- 2008
- Issue
- 4
- Pages
- CD002276-CD002276
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2097010829
- Cited by
- 40
- References
- 6
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug treatment for facioscapulohumeral muscular dystrophy. https://app.cochat.ai/papers/10.1002/14651858.cd002276.pub2
- The paper
- Rose, M. R., & Tawil, R. (2004). Drug treatment for facioscapulohumeral muscular dystrophy. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd002276.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.